In a previous study, we found that the presence of the NPM1 gene mutation was negatively associated with the susceptibility of FLT3-ITD AML cells to the FLT3 inhibitor midostaurin and the MDM2 inhibitor NVP-HDM201 [41]. This evidence concerns the gene NPM1 and acute myeloid leukemia.